Massachusetts biopharma workforce growth was fairly flat last year, and R&D and manufacturing employment declined, according ...

Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is ...

BioSpace did a deep dive into biopharma female executives who navigated difficult markets to lead their companies to ...

The layoffs will affect employees at Pfizer’s Bothell, Washington site, which previously served as the headquarters for ...

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities ...

Novartis has bet up to $772 million to gain access to BioArctic’s BrainTransporter platform, which was leveraged in a ...

AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year— was ...

Appia Bio's shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the ...

As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers ...